David Lawrence

7.8k total citations · 3 hit papers
87 papers, 3.4k citations indexed

About

David Lawrence is a scholar working on Physiology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, David Lawrence has authored 87 papers receiving a total of 3.4k indexed citations (citations by other indexed papers that have themselves been cited), including 42 papers in Physiology, 35 papers in Pulmonary and Respiratory Medicine and 12 papers in Molecular Biology. Recurrent topics in David Lawrence's work include Asthma and respiratory diseases (26 papers), Chronic Obstructive Pulmonary Disease (COPD) Research (21 papers) and Smoking Behavior and Cessation (18 papers). David Lawrence is often cited by papers focused on Asthma and respiratory diseases (26 papers), Chronic Obstructive Pulmonary Disease (COPD) Research (21 papers) and Smoking Behavior and Cessation (18 papers). David Lawrence collaborates with scholars based in United States, United Kingdom and Switzerland. David Lawrence's co-authors include Robert M. Anthenelli, Thomas McRae, Neal L. Benowitz, Robert West, A. Eden Evins, Cristina Russ, Alok Krishen, John A. Ascher, J. Taylor Hays and Benjamin Krämer and has published in prestigious journals such as The Lancet, JAMA and Circulation.

In The Last Decade

David Lawrence

84 papers receiving 3.3k citations

Hit Papers

Neuropsychiatric safety and efficacy of varenicline, bupr... 2013 2026 2017 2021 2016 2013 2022 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial
    2016 632 citations Robert M. Anthenelli, Neal L. Benowitz et al. profile →
  2. Imatinib Mesylate as Add-on Therapy for Pulmonary Arterial Hypertension
    2013 411 citations Marius M. Hoeper, Robyn J. Barst et al. Circulation profile →
  3. Inclisiran and cardiovascular events: a patient-level analysis of phase III trials
    2022 131 citations Kausik K. Ray, Frederick J. Raal et al. European Heart Journal profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
David Lawrence United States 25 1.5k 1.3k 553 381 327 87 3.4k
David Burns United States 36 1.4k 0.9× 611 0.5× 1.2k 2.2× 192 0.5× 319 1.0× 121 4.9k
Yisheng Li United States 38 1.3k 0.8× 702 0.5× 728 1.3× 111 0.3× 212 0.6× 209 5.3k
Catherine Corey United States 33 2.8k 1.8× 724 0.5× 774 1.4× 175 0.5× 139 0.4× 64 4.6k
Xifeng Wu United States 27 1.1k 0.7× 532 0.4× 1.3k 2.4× 354 0.9× 293 0.9× 75 3.9k
Ian Pagano United States 35 1.4k 0.9× 1.3k 1.0× 544 1.0× 62 0.2× 204 0.6× 147 4.7k
Hong Gwan Seo South Korea 25 666 0.4× 666 0.5× 311 0.6× 64 0.2× 457 1.4× 80 3.0k
Christopher Hyde United Kingdom 39 413 0.3× 597 0.4× 464 0.8× 364 1.0× 1.1k 3.4× 115 5.6k
Donald R. Shopland United States 25 1.1k 0.7× 340 0.3× 352 0.6× 70 0.2× 118 0.4× 42 2.5k
Gretchen Kimmick United States 40 584 0.4× 902 0.7× 349 0.6× 287 0.8× 276 0.8× 162 5.0k
Virginia L. Ernster United States 44 760 0.5× 853 0.6× 575 1.0× 269 0.7× 610 1.9× 91 8.8k

Countries citing papers authored by David Lawrence

Since Specialization
Citations

This map shows the geographic impact of David Lawrence's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Lawrence with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Lawrence more than expected).

Fields of papers citing papers by David Lawrence

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Lawrence. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Lawrence. The network helps show where David Lawrence may publish in the future.

Co-authorship network of co-authors of David Lawrence

This figure shows the co-authorship network connecting the top 25 collaborators of David Lawrence. A scholar is included among the top collaborators of David Lawrence based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Lawrence. David Lawrence is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Kypriotakis, George, Paul M. Cinciripini, Charles E. Green, et al.. (2024). Effects of Varenicline, Bupropion, Nicotine Patch, and Placebo on Treating Smoking Among Persons With Current or Past Major Depressive Disorder: Secondary Analysis of a Double-Blind, Randomized, Placebo-Controlled Trial. American Journal of Psychiatry. 182(2). 174–186. 1 indexed citations
2.
Zyl-Smit, Richard N. van, Kenneth R. Chapman, Huib A.M. Kerstjens, et al.. (2023). Mometasone/Indacaterol/Glycopyrronium (MF/IND/GLY) and MF/IND at Different MF Strengths versus Fluticasone Propionate/Salmeterol Xinafoate (FLU/SAL) and FLU/SAL+ Tiotropium in Patients with Asthma. Journal of Asthma and Allergy. Volume 16. 123–134.
3.
Κostikas, Κonstantinos, Jorge Máspero, Kenneth R. Chapman, et al.. (2023). Efficacy of mometasone/indacaterol/glycopyrronium in patients with inadequately controlled asthma with respect to baseline eosinophil count: Post hoc analysis of IRIDIUM study. Respiratory Medicine. 217. 107334–107334. 3 indexed citations
4.
Zyl-Smit, Richard N. van, Huib A.M. Kerstjens, Jorge Máspero, et al.. (2023). Triple Therapy with Mometasone/Indacaterol/Glycopyrronium or Doubling the ICS/LABA Dose in GINA Step 4: IRIDIUM Analyses. Pulmonary Therapy. 9(3). 395–409. 2 indexed citations
5.
Ray, Kausik K., Frederick J. Raal, David Kallend, et al.. (2022). Inclisiran and cardiovascular events: a patient-level analysis of phase III trials. European Heart Journal. 44(2). 129–138. 131 indexed citations breakdown →
6.
Holzhauer, Björn, Lisa V. Hampson, John Paul Gosling, et al.. (2022). Eliciting judgements about dependent quantities of interest: The SHeffield ELicitation Framework extension and copula methods illustrated using an asthma case study. Pharmaceutical Statistics. 21(5). 1005–1021. 5 indexed citations
7.
Tønnesen, Philip, David Lawrence, & Serena Tonstad. (2022). Medication-assisted quit rates in participants with smoking-relateddiseases in EAGLES: Post hoc analyses of a double-blind,randomized, placebo-controlled clinical trial. Tobacco Induced Diseases. 20(May). 1–11. 8 indexed citations
8.
Schabath, Matthew B., Tapashi Dalvi, Hongyue Dai, et al.. (2019). <p>A Molecular Epidemiological Analysis Of Programmed Cell Death Ligand-1 (PD-L1) Protein Expression, Mutations And Survival In Non-Small Cell Lung Cancer</p>. Cancer Management and Research. Volume 11. 9469–9481. 1 indexed citations
9.
Ayers, Catherine R., Jaimee L. Heffner, Cristina Russ, et al.. (2019). Efficacy and safety of pharmacotherapies for smoking cessation in anxiety disorders: Subgroup analysis of the randomized, active‐ and placebo‐controlled EAGLES trial. Depression and Anxiety. 37(3). 247–260. 13 indexed citations
10.
Benowitz, Neal L., Andrew Pipe, Robert West, et al.. (2018). Cardiovascular Safety of Varenicline, Bupropion, and Nicotine Patch in Smokers. JAMA Internal Medicine. 178(5). 622–622. 93 indexed citations
11.
Jänne, Pasi A., Michel M. van den Heuvel, Fabrice Barlési, et al.. (2016). Selumetinib in combination with docetaxel as second-line treatment for patients with KRAS-mutant advanced NSCLC: Results from the phase III SELECT-1 trial. Annals of Oncology. 27. vi583–vi583. 10 indexed citations
12.
Hoeper, Marius M., Robyn J. Barst, Robert C. Bourge, et al.. (2013). Imatinib Mesylate as Add-on Therapy for Pulmonary Arterial Hypertension. Circulation. 127(10). 1128–1138. 411 indexed citations breakdown →
13.
Decramer, Marc, Kenneth R. Chapman, Ronald Dahl, et al.. (2013). Once-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): a randomised, blinded, parallel-group study. The Lancet Respiratory Medicine. 1(7). 524–533. 194 indexed citations
14.
To, Yasuo, Masaharu Kinoshita, Sang Haak Lee, et al.. (2012). Assessing efficacy of indacaterol in moderate and severe COPD patients: A 12-week study in an Asian population. Respiratory Medicine. 106(12). 1715–1721. 9 indexed citations
15.
Decramer, Marc, Andrea Rossi, David Lawrence, & Danny McBryan. (2012). Indacaterol therapy in patients with COPD not receiving other maintenance treatment. Respiratory Medicine. 106(12). 1706–1714. 13 indexed citations
16.
O’Donnell, Denis E., Richard Casaburi, Walter Vincken, et al.. (2011). Effect of indacaterol on exercise endurance and lung hyperinflation in COPD. Respiratory Medicine. 105(7). 1030–1036. 114 indexed citations
17.
Tashkin, Donald P., et al.. (2011). Lung function and respiratory symptoms in a 1-year randomized smoking cessation trial of varenicline in COPD patients. Respiratory Medicine. 105(11). 1682–1690. 36 indexed citations
18.
Korn, Stephanie, Oliver Kornmann, Leonard Dunn, et al.. (2011). Efficacy of indacaterol is maintained in patients with moderate or less and severe or worse COPD. European Respiratory Journal. 38(Suppl 55). p860–p860. 2 indexed citations
19.
Woessner, Ralph, et al.. (2010). Efficacy, Safety and Pharmacokinetics of Indacaterol in Caucasian and Japanese Patients with Chronic Obstructive Pulmonary Disease. Clinical Drug Investigation. 31(4). 247–255. 13 indexed citations
20.
Gothard, Lone, A.W.B. Stanton, David Lawrence, et al.. (2003). Non-randomised phase II trial of hyperbaric oxygen therapy in patients with chronic arm lymphoedema and tissue fibrosis after radiotherapy for early breast cancer. Radiotherapy and Oncology. 70(3). 217–224. 63 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by David Burns Breakdown of academic impact, for papers by Yisheng Li Breakdown of academic impact, for papers by Catherine Corey Breakdown of academic impact, for papers by Xifeng Wu Breakdown of academic impact, for papers by Ian Pagano Breakdown of academic impact, for papers by Hong Gwan Seo Breakdown of academic impact, for papers by Christopher Hyde Breakdown of academic impact, for papers by Donald R. Shopland Breakdown of academic impact, for papers by Gretchen Kimmick Breakdown of academic impact, for papers by Virginia L. Ernster
Rankless by CCL
2026